Citigroup Maintains Buy on Guardant Health, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $40 to $45.
August 08, 2024 | 7:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Patrick Donnelly maintains a Buy rating on Guardant Health and raises the price target from $40 to $45.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact Guardant Health's stock price in the short term as it signals confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100